Header Logo

Connection

Barry Maron to Defibrillators, Implantable

Back to Details
This is a "connection" page, showing publications Barry Maron has written about Defibrillators, Implantable.
Barry Maron
Connection Strength
19.239
Defibrillators, Implantable
  1. Maron MS, Rowin EJ, Maron BJ. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024 02 01; 212S:S64-S76.
    View in: PubMed
    Score: 0.709
  2. Maron BJ, Estes NAM, Rowin EJ, Maron MS, Reynolds MR. Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2023 07 25; 82(4):353-373.
    View in: PubMed
    Score: 0.684
  3. Maron MS, Rowin EJ, Bonaventura J, Maron BJ. Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field? Am J Cardiol. 2023 08 01; 200:236-238.
    View in: PubMed
    Score: 0.681
  4. Maron MS, Rowin E, Spirito P, Maron BJ. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023 03 27; 109(8):589-594.
    View in: PubMed
    Score: 0.669
  5. Maron BJ, Rowin EJ, Madias C, Dolan N, Maron MS. Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). Am J Cardiol. 2022 04 01; 168:163-165.
    View in: PubMed
    Score: 0.618
  6. Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annu Rev Med. 2022 01 27; 73:363-375.
    View in: PubMed
    Score: 0.617
  7. Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, Marsy D, Heitner SB, Cohen E, Leong KMW, Winters SL, Martinez MW, Koethe BC, Rakowski H, Maron BJ. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2022 05; 19(5):782-789.
    View in: PubMed
    Score: 0.612
  8. Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021 06; 18(6):1012-1023.
    View in: PubMed
    Score: 0.575
  9. Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
    View in: PubMed
    Score: 0.570
  10. Maron BJ, Estes NAM. The "Guidant Affair": 15 years later. Heart Rhythm. 2021 03; 18(3):487-488.
    View in: PubMed
    Score: 0.565
  11. Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
    View in: PubMed
    Score: 0.560
  12. Maron MS, Steiger N, Burrows A, Madias C, Weinstock J, Link MS, Rowin EJ, Maron BJ. Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2020 08; 6(8):1019-1021.
    View in: PubMed
    Score: 0.556
  13. Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.
    View in: PubMed
    Score: 0.548
  14. Maron BJ, Harris KM, Maron MS. The Guidant Affair revisited?but this time with good news. Heart Rhythm. 2020 03; 17(3):512-513.
    View in: PubMed
    Score: 0.525
  15. Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019 07 01; 4(7):644-657.
    View in: PubMed
    Score: 0.516
  16. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
    View in: PubMed
    Score: 0.473
  17. Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. J Cardiovasc Electrophysiol. 2017 May; 28(5):531-537.
    View in: PubMed
    Score: 0.441
  18. Maron BJ, Maron MS. LGE Means Better Selection of HCM?Patients for Primary Prevention Implantable Defibrillators. JACC Cardiovasc Imaging. 2016 12; 9(12):1403-1406.
    View in: PubMed
    Score: 0.421
  19. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016 05; 13(5):1155-1165.
    View in: PubMed
    Score: 0.405
  20. Maron BJ. Historical perspectives on the implantable cardioverter-defibrillator and prevention of sudden death in hypertrophic cardiomyopathy. Card Electrophysiol Clin. 2015 Jun; 7(2):165-71.
    View in: PubMed
    Score: 0.385
  21. Maron BJ, Weiner HL, Maron MS, Roberts WC. Surviving malignant hypertrophic cardiomyopathy with all major complications in a single patient. Am J Cardiol. 2015 Feb 01; 115(3):402-4.
    View in: PubMed
    Score: 0.374
  22. Maron BJ, Nishimura RA. Revisiting arrhythmic risk after alcohol septal ablation: is the pendulum finally swinging?back to myectomy? JACC Heart Fail. 2014 Dec; 2(6):637-40.
    View in: PubMed
    Score: 0.373
  23. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 09; 61(14):1527-35.
    View in: PubMed
    Score: 0.335
  24. Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm. 2013 Feb; 10(2):214-8.
    View in: PubMed
    Score: 0.323
  25. Maron BJ, Braunwald E. Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease. Circulation. 2012 Sep 25; 126(13):1640-4.
    View in: PubMed
    Score: 0.323
  26. Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J. 2010 Nov; 74(11):2271-82.
    View in: PubMed
    Score: 0.282
  27. Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010 Jun 15; 105(12):1842-3.
    View in: PubMed
    Score: 0.276
  28. Maron BJ. Dr. Gunnar Thor Gunnarsson and hypertrophic cardiomyopathy: what "giving back" means. Am J Cardiol. 2010 Jan 15; 105(2):277-8.
    View in: PubMed
    Score: 0.268
  29. Maron BJ, Spirito P. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Apr; 37(4):297-302.
    View in: PubMed
    Score: 0.254
  30. Maron BJ, Semsarian C, Shen WK, Link MS, Epstein AE, Estes NA, Almquist A, Giudici MC, Haas TS, Hodges JS, Spirito P. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm. 2009 May; 6(5):599-602.
    View in: PubMed
    Score: 0.251
  31. Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008 Oct; 19(10):1118-26.
    View in: PubMed
    Score: 0.237
  32. Maron BJ, Zipes DP. It is not prudent to allow all athletes with implantable-cardioverter defibrillators to participate in all sports. Heart Rhythm. 2008 Jun; 5(6):864-6.
    View in: PubMed
    Score: 0.234
  33. Almquist AK, Hanna CA, Haas TS, Maron BJ. Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008 Mar; 19(3):319-22.
    View in: PubMed
    Score: 0.227
  34. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007 Jul 25; 298(4):405-12.
    View in: PubMed
    Score: 0.226
  35. Adabag AS, Maron BJ. Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol. 2007 Apr; 12(2):171-80.
    View in: PubMed
    Score: 0.221
  36. Maron BJ, Olivotto I, Maron MS. The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? Eur Heart J. 2006 Aug; 27(16):1895-7.
    View in: PubMed
    Score: 0.210
  37. Hauser RG, Maron BJ. Lessons from the failure and recall of an implantable cardioverter-defibrillator. Circulation. 2005 Sep 27; 112(13):2040-2.
    View in: PubMed
    Score: 0.199
  38. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm. 2005 Aug; 2(8):814-9.
    View in: PubMed
    Score: 0.197
  39. Gornick CC, Hauser RG, Almquist AK, Maron BJ. Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. Heart Rhythm. 2005 Jul; 2(7):681-3.
    View in: PubMed
    Score: 0.196
  40. Narayanan CA, Bokhari N, Rowin EJ, Maron MS, Maron BJ, Link MS, Madias C. Maintenance of Subcutaneous Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy Patients With Iatrogenic Left Bundle-Branch Block After Septal Myectomy. J Am Heart Assoc. 2024 Apr 16; 13(8):e033728.
    View in: PubMed
    Score: 0.179
  41. Maron BJ, Estes NA, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003 Jun 17; 107(23):2872-5.
    View in: PubMed
    Score: 0.170
  42. Abdelfattah OM, Martinez M, Sayed A, ElRefaei M, Abushouk AI, Hassan A, Masri A, Winters SL, Kapadia SR, Maron BJ, Rowin E, Maron MS. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2022 11; 8(11):1417-1427.
    View in: PubMed
    Score: 0.162
  43. Maron BJ. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Cardiol Rev. 2002 May-Jun; 10(3):173-81.
    View in: PubMed
    Score: 0.157
  44. Papanastasiou CA, Zegkos T, Karamitsos TD, Rowin EJ, Maron MS, Parcharidou D, Kokkinidis DG, Karvounis H, Rimoldi O, Maron BJ, Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2021 06 01; 332:127-132.
    View in: PubMed
    Score: 0.146
  45. Maron BJ, Rowin EJ, Maron MS. After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature? Am J Cardiol. 2021 03 01; 142:136-137.
    View in: PubMed
    Score: 0.143
  46. Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? Am J Med. 2020 08; 133(8):886-888.
    View in: PubMed
    Score: 0.139
  47. Kumar KR, Mandleywala SN, Madias C, Weinstock J, Rowin EJ, Maron BJ, Maron MS, Link MS. Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 06 15; 125(12):1896-1900.
    View in: PubMed
    Score: 0.136
  48. Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 04 15; 121(8):986-996.
    View in: PubMed
    Score: 0.117
  49. Estes NAM, Maron BJ. Defibrillation threshold testing in hypertrophic cardiomyopathy: As SIMPLE as possible but not simpler. Heart Rhythm. 2018 03; 15(3):393-394.
    View in: PubMed
    Score: 0.116
  50. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, Calkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL, Zipes DP, Berul CI, Cheng A, Jordaens L, Law I, Loomis M, Willems R, Barth C, Broos K, Brandt C, Dziura J, Li F, Simone L, Vandenberghe K, Cannom D. Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Long-Term Results of a Prospective Multinational Registry. Circulation. 2017 06 06; 135(23):2310-2312.
    View in: PubMed
    Score: 0.112
  51. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 06 01; 119(11):1862-1865.
    View in: PubMed
    Score: 0.110
  52. Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
    View in: PubMed
    Score: 0.110
  53. Maron BJ, Nishimura RA, Maron MS. Shared decision-making in HCM. Nat Rev Cardiol. 2017 03; 14(3):125-126.
    View in: PubMed
    Score: 0.109
  54. Konstantinou DM, Efthimiadis GK, Vassilikos V, Paraskevaidis S, Pagourelias E, Maron BJ, Karvounis H. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2016 Jun; 17(6):433-9.
    View in: PubMed
    Score: 0.104
  55. Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
    View in: PubMed
    Score: 0.097
  56. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
    View in: PubMed
    Score: 0.097
  57. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, Calkins H, Estes NA, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL, Zipes DP, Berul CI, Cheng A, Law I, Loomis M, Barth C, Brandt C, Dziura J, Li F, Cannom D. Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation. 2013 May 21; 127(20):2021-30.
    View in: PubMed
    Score: 0.084
  58. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, Gersh BJ, Ommen SR. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010 Nov 15; 106(10):1481-6.
    View in: PubMed
    Score: 0.071
  59. Maron BJ. Can sudden cardiac death be prevented? Cardiovasc Pathol. 2010 Nov-Dec; 19(6):329-35.
    View in: PubMed
    Score: 0.068
  60. Sherrid MV, Cotiga D, Hart D, Ehlert F, Haas TS, Shen WK, Link MS, Estes NA, Epstein AE, Semsarian C, Daubert JP, Winters SL, Giudici MC, Maron BJ. Relation of 12-lead electrocardiogram patterns to implanted defibrillator-terminated ventricular tachyarrhythmias in hypertrophic cardiomyopathy. Am J Cardiol. 2009 Dec 15; 104(12):1722-6.
    View in: PubMed
    Score: 0.067
  61. Maron BJ. Sudden death in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009 Dec; 2(4):368-80.
    View in: PubMed
    Score: 0.066
  62. Spirito P, Autore C, Rapezzi C, Bernab? P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barill? CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009 Apr 07; 119(13):1703-10.
    View in: PubMed
    Score: 0.063
  63. Maron BJ, Haas TS, Shannon KM, Almquist AK, Hodges JS. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm. 2009 Jul; 6(7):993-7.
    View in: PubMed
    Score: 0.063
  64. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008 Oct 07; 118(15):1541-9.
    View in: PubMed
    Score: 0.061
  65. Hauser RG, Maron BJ, Marine JE, Lampert R, Kadish AH, Winters SL, Scher DL, Biria M, Kalia A. Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. Heart Rhythm. 2008 Nov; 5(11):1517-22.
    View in: PubMed
    Score: 0.061
  66. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, Appelbaum E, Main ML, Roberts WC. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol. 2008 Feb 15; 101(4):544-7.
    View in: PubMed
    Score: 0.058
  67. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005 Oct; 10(4 Suppl):67-83.
    View in: PubMed
    Score: 0.050
  68. Maron BJ. Ten common questions about hypertrophic cardiomyopathy...and misconceptions. Cardiol Rev. 2005 Mar-Apr; 13(2):59-60.
    View in: PubMed
    Score: 0.048
  69. Link MS, Maron BJ, Stickney RE, Vanderbrink BA, Zhu W, Pandian NG, Wang PJ, Estes NA. Automated external defibrillator arrhythmia detection in a model of cardiac arrest due to commotio cordis. J Cardiovasc Electrophysiol. 2003 Jan; 14(1):83-7.
    View in: PubMed
    Score: 0.041
  70. Maron BJ. Cardiology patient pages. Hypertrophic cardiomyopathy. Circulation. 2002 Nov 05; 106(19):2419-21.
    View in: PubMed
    Score: 0.041
  71. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, Maron MS. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2020 06 23; 75(24):3033-3043.
    View in: PubMed
    Score: 0.035
  72. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol. 2009 Apr; 20(4):445-7.
    View in: PubMed
    Score: 0.015
  73. Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004 Feb; 127(2):481-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.